AUROBINDO

February 1, 2016

Surveillance Department,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED,
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
MUMBAI - 400 051

Dear Sirs,

Sub: Clarification on News Item

Ref: 1) Your Letter No.NSE/CM/Surveillance/R-247 dated February 1, 2016
2) Our Company Code No. AUROPHARMA

We refer to your letter dated 01.02.2016, with regard to the news item which appeared in www.Moneycontrol.com on the USFDA inspection in Unit III and Unit VII of the Company. This is to clarify that the said facilities underwent pre-approval inspection by USFDA and there was no Form 483 issued for Unit III. With regards to Unit VII, there were certain observations. The Company is appropriately responding and this has no perceived impact on the operations and exports from the said facility.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

A.MOHAN RAMI REDDY
Vice President (Legal) & Company Secretary

AUROBINDO PHARMA LTD. HYD.